As researchers found that chemical modifications across a cell’s RNA were seemingly distorted in some cancers, a trio of biotechnology companies spawned: Storm Therapeutics, Accent Therapeutics and Gotham Therapeutics. On Thursday, 2017-founded Accent raised $63 million in a Series B round, led by EcoR1 Capital.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,